All articles by Manasi Vaidya
Manasi Vaidya is the lead editor for Pharmaceutical Technology where she covers the healthcare space. She writes features that look at the research, regulation and reimbursement of drugs with a focus on topics at the intersection of business and science. She is based in Brooklyn and an alum of New York University’s Science, Health and Environmental Reporting program.
Manasi Vaidya
@manasivaidya22
FDA raises alarm about weight-gain supplement apetamin
The US FDA has warned that the illegally imported supplement apetamin has been linked to several adverse events.
Magazine: Nanoparticle drug delivery research gets a boost
In this issue: mRNA Covid-19 vaccine success drives nanoparticle research, eConsent in clinical trials, digital inhalers, controversies surrounding primate models, and more.
Magazine: Dawn of a new indication: How to study drugs for aging
In this issue: Developing drugs for aging, sustainable cleanroom tech, digital therapeutics to improve neurological outcomes, cloud-related advances, and more.
CMO Moves: Regulatory catalysts for drug manufacturing – March 2023
Pharmaceutical Technology analyses recent regulatory and trial announcements that are likely to impact therapy manufacturing plans.
Brazil’s ANVISA approves Takeda’s dengue vaccine Qdenga
Qdenga’s approval is supported by the data obtained from 19 clinical trials, and follows similar decisions in other countries.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
Magazine: ‘Right shoring’ API production in Europe
In this issue: Right shoring API production in Europe, the hunt for an Alzheimer’s disease vaccine, key trends for decentralised clinical trials in 2023, and more.
CMO Moves: Regulatory catalysts for drug manufacturing- February
Pharmaceutical Technology analyses recent regulatory announcements that will likely impact therapy manufacturing plans.
Magazine: CRISPR gene therapies cut through in 2023
In this issue: CRISPR gene therapy milestones in 2023, analysing major deal trends in pharma, regulating artificial intelligence use in pharma, and more.
CMO Moves: Regulatory catalysts for therapy manufacturing -January
Pharmaceutical Technology analyses recent regulatory announcements that will likely impact therapy manufacturing plans.
Biosimilar Q&A: Is an interchangeability designation still relevant?
Heidi Hunter, former President of Cardinal Health Specialty Solutions discusses trends influencing the use and reimbursement of biosimilars.